The market pushed Johnson & Johnson up about 2% today after the Q3 print, yet the real story is far less euphoric. Adjusted earnings per share slipped year over year, while a roughly US$7b stack of litigation and deal related charges compressed reported profit and left GAAP EPS at only US$0.09. Investors who came in after a weak 7 day and 30 day stretch just saw a relief bounce. The key question now is whether that single day pop reflects confidence in the underlying pharmaceuticals engine or...

The pharma company is on track to reach $100 billion in recorded revenue despite “temporary” headwinds in its medtech segment, executives said.

/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) shareholders took losses after a recent quarterly report showed MedTech segment sales falling short of Wall...

Key Stats for Johnson and Johnson StockPrice change for Johnson and Johnson stock in the last 6 months: 4%$JNJ Stock Price as of Oct. 13: $24952-Week High: $281$JNJ Stock Price Target: $280What Happened?Johnson & Johnson (JNJ:NYSE) beat third-quarter estimates on Tuesday, but the stock still fell because sales in its medical devices business, MedTech, were weak.

Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The lineup includes ICOTYDE, an oral treatment for plaque psoriasis. The company has yet to disclose sales figures for the medication. How much the drug can ultimately add to J&J remains an open question. Anyone purchasing shares today takes on that unknown before the answer is in.

Johnson & Johnson (JNJ) just paired a stronger full year outlook with an earnings beat, yet the stock sold off as weak MedTech performance and a large talc litigation charge grabbed investor attention. That sharp 5.7% drop in the latest trading session sits against a much stronger backdrop, with Johnson & Johnson posting a year to date share price return of 19.9% and a 1 year total shareholder return of 33.2%, supported by drug data like TREMFYA and ICOTYDE, the Firefly Bio acquisition and...

Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a warning.

NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) released its Q3 2026 financial results yesterday, highlighted by a 5.9 percent increase in worldwide sales to $25.4 billion. Operational growth reached 6.0 percent for the quarter and the company’s Innovative Medicine segment generated $16.8 billion, representing a 7.7 percent reported gain.